DUBLIN – With little appetite for biotech in its home market, Finnish biotech firm Faron Pharmaceuticals Oy is seeking £20 million (US$30.5 million) in an IPO on the Alternative Investment Market (AIM) of the London Stock Exchange, to fund a phase III trial of its lead drug, Traumakine (FP-1201, interfero-beta-1a), in acute respiratory distress syndrome (ARDS).